Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 18/20 | 0.70 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.59 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.59 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19732211 | 0.88 | FGFR1 (0.54) | FGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL16659510 | 0.88 | FGFR1 (0.89) | FGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL16659446 | 0.82 | FGFR1 (1.00) | FGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL16659433 | 0.82 | FGFR1 (1.00) | FGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL23889756 | 0.81 | FGFR1 (0.76) | FGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL17728854 | 0.76 | FGFR1 (1.00) | FGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL16654878 | 0.75 | FGFR1 (1.00) | FGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL16655985 | 0.75 | FGFR1 (0.90) | FGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL16659468 | 0.75 | FGFR1 (1.00) | FGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL16659606 | 0.74 | FGFR2 (1.00) | FGFR1FGFR2FGFR3FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360785-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360785-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | FGFR1 2/4885FGFR2 4/4885FGFR3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.